𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Platelet-Derived Growth Factor Receptor Inhibitor Imatinib Mesylate and Docetaxel: A Modular Phase I Trial in Androgen-Independent Prostate Cancer

✍ Scribed by Mathew, P.

Book ID
121882159
Publisher
American Society of Clinical Oncology
Year
2004
Tongue
English
Weight
303 KB
Volume
22
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Platelet-derived growth factor receptor
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer: Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C., Department of Genitourinary Medical Oncology, Unit 427, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX. J Clin Oncol 2004;22:3323–9
✍ Gurkamal Chatta πŸ“‚ Article πŸ“… 2004 πŸ› Elsevier Science 🌐 English βš– 45 KB
Imatinib mesylate for targeting the plat
Imatinib mesylate for targeting the platelet-derived growth factor Ξ² receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancerβ€”A dose-escalation Phase I trial
✍ Salah-Eddin Al-Batran; Akin Atmaca; Eberhard Schleyer; Claudia Pauligk; Christia πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 188 KB

## Abstract ## BACKGROUND. In previous experimental models, because of its ability to inhibit the activity of platelet‐derived growth factor Ξ² receptor, imatinib decreased the interstitial fluid pressure and improved the delivery and efficacy of anticancer drugs, including fluorouracil. The object